GI
TEVA icon

Gradient Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Gradient Investments’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-474
Closed -$7.7K – 1182
2024
Q2 		$7.7K Buy
474
+274
+137% +$4.22K ﹤0.01% 787
2024
Q1 		$2.82K Sell
200
-951
-83% -$12K ﹤0.01% 807
2023
Q4 		$12K Sell
1,151
-800
-41% -$7.47K ﹤0.01% 803
2023
Q3 		$19.9K Buy
1,951
+800
+70% +$7.45K ﹤0.01% 682
2023
Q2 		$8.67K Hold
1,151
– – ﹤0.01% 833
2023
Q1 		$10.2K Buy
1,151
+951
+476% +$9.4K ﹤0.01% 812
2022
Q4 		$1.82K Sell
200
-800
-80% -$6.98K ﹤0.01% 1105
2022
Q3 		$8K Hold
1,000
– – ﹤0.01% 857
2022
Q2 		$8K Hold
1,000
– – ﹤0.01% 827
2022
Q1 		$9K Buy
1,000
+800
+400% +$6.68K ﹤0.01% 801
2021
Q4 		$2K Hold
200
– – ﹤0.01% 1096
2021
Q3 		$2K Hold
200
– – ﹤0.01% 1033
2021
Q2 		$2K Hold
200
– – ﹤0.01% 1020
2021
Q1 		$2K Sell
200
-132
-40% -$1.51K ﹤0.01% 1032
2020
Q4 		$3K Hold
332
– – ﹤0.01% 906
2020
Q3 		$3K Buy
332
+132
+66% +$1.4K ﹤0.01% 911
2020
Q2 		$2K Hold
200
– – ﹤0.01% 916
2020
Q1 		$2K Hold
200
– – ﹤0.01% 938
2019
Q4 		$2K Sell
200
-43
-18% -$384 ﹤0.01% 963
2019
Q3 		$2K Buy
243
+43
+22% +$329 ﹤0.01% 943
2019
Q2 		$2K Buy
+200
New +$2.41K ﹤0.01% 900
2018
Q2 		– Sell
-13
Closed – – 1134
2018
Q1 		$0 Hold
13
– – ﹤0.01% 1156
2017
Q4 		$0 Buy
+13
New +$196 ﹤0.01% 1083
2017
Q3 		– Sell
-24,090
Closed -$800K – 661
2017
Q2 		$800K Buy
24,090
+16,386
+213% +$507K 0.06% 110
2017
Q1 		$247K Buy
7,704
+7,500
+3,676% +$256K 0.02% 214
2016
Q4 		$7K Buy
204
+194
+1,940% +$7.75K ﹤0.01% 506
2016
Q3 		$0 Hold
10
– – ﹤0.01% 775
2016
Q2 		$0 Sell
10
-149
-94% -$7.93K ﹤0.01% 792
2016
Q1 		$8K Buy
159
+59
+59% +$3.46K ﹤0.01% 473
2015
Q4 		$7K Hold
100
– – ﹤0.01% 447
2015
Q3 		$6K Hold
100
– – ﹤0.01% 438
2015
Q2 		$6K Buy
100
+8
+9% +$494 ﹤0.01% 450
2015
Q1 		$6K Buy
+92
New +$5.35K ﹤0.01% 473
2014
Q1 		– Sell
-63
Closed -$3K – 623
2013
Q4 		$3K Buy
+63
New +$2.48K ﹤0.01% 481

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Gradient Investments's TEVA Position: Q3 2024 in Review

Gradient Investments sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 474 shares — an estimated $7.7K sold.

Gradient Investments first reported a position in TEVA in Q4 2013 and held it in 34 quarters. The position peaked at $800K in Q2 2017. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Gradient Investments reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Gradient Investments sold 474 Teva Pharmaceuticals shares in Q3 2024, an estimated $7.7K.
  • Gradient Investments first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 34 quarters.
  • Gradient Investments's Teva Pharmaceuticals position peaked at $800K in Q2 2017.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.